Status:
COMPLETED
Observation of Treatment Patterns With Lucentis in Approved Indications
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV
Eligibility:
All Genders
18+ years
Brief Summary
A multicentre, open-label, non-interventional study to observe treatment patterns in patients with wet age-related macular degeneration (wAMD), with visual impairment due to diabetic macular edema (DM...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Presence of
- neovascular (wet) age-related macular degeneration (AMD),
- visual impairment due to diabetic macular oedema (DME),
- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) or
- visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM)
- Patients for whom a therapy with Lucentis® is medically indicated.
- Written patients informed consent.
- Exclusion criteria:
- As described in the SmPC.
- Preceding intravitreal treatment of the study eye with anti-VEGF drugs in the last three months before enrollment
- Preceding intravitreal treatment of the study eye with steroids
Exclusion
Key Trial Info
Start Date :
December 8 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2016
Estimated Enrollment :
5778 Patients enrolled
Trial Details
Trial ID
NCT02194803
Start Date
December 8 2011
End Date
December 31 2016
Last Update
March 1 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Tübingen, Germany, 72076